CN114224919A - Pharmaceutical composition for relieving depression and preparation method thereof - Google Patents
Pharmaceutical composition for relieving depression and preparation method thereof Download PDFInfo
- Publication number
- CN114224919A CN114224919A CN202111443408.2A CN202111443408A CN114224919A CN 114224919 A CN114224919 A CN 114224919A CN 202111443408 A CN202111443408 A CN 202111443408A CN 114224919 A CN114224919 A CN 114224919A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- folic acid
- composition according
- vitamins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 14
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940093265 berberine Drugs 0.000 claims abstract description 12
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000002224 folic acids Chemical class 0.000 claims abstract description 12
- 235000021323 fish oil Nutrition 0.000 claims abstract description 10
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 claims abstract description 9
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 claims abstract description 9
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000005303 weighing Methods 0.000 claims abstract description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 19
- 235000019156 vitamin B Nutrition 0.000 claims description 13
- 239000011720 vitamin B Substances 0.000 claims description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 229940065207 methylfolic acid Drugs 0.000 claims description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 239000011669 selenium Substances 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- -1 patches Substances 0.000 claims description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000126 substance Chemical class 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000000052 comparative effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 244000241838 Lycium barbarum Species 0.000 description 3
- 235000015459 Lycium barbarum Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000132446 Inula Species 0.000 description 2
- 241000244365 Ligusticum sinense Species 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- 241001346334 Amomum tsao-ko Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000046585 Aristolochia clematitis Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 244000024469 Cucumis prophetarum Species 0.000 description 1
- 235000010071 Cucumis prophetarum Nutrition 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- KJAQRHMKLVGSCG-UHFFFAOYSA-N propan-2-ylhydrazine Chemical compound CC(C)NN KJAQRHMKLVGSCG-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal composition for relieving depression and a preparation method thereof, and relates to the technical field of Chinese medicinal preparations. The pharmaceutical composition for relieving depression comprises berberine, liensinine, lycium barbarum polysaccharide, folic acid compounds and fish oil. Weighing the components according to the prescription amount, respectively, smashing into powder with the granularity range of 30-40 meshes, filtering into fine powder with gauze with the granularity range of 80-120 meshes, and uniformly mixing to obtain the powder. The pharmaceutical composition for relieving depression and the preparation method thereof can effectively relieve depression, and have the advantages of simple preparation and basically no toxic or side effect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a medicinal composition for relieving depression and a preparation method thereof.
Background
Depression, also known as depressive disorder, is characterized clinically by a marked and persistent depression in the mood, the main type of mood disorder. The low mood is not matched with the situation in clinic, the depression of the mood can be from sultriness to sadness, and the self-declining depression and even the pessimism are taken away, and suicide attempts or behaviors can be caused; even the occurrence of stupor; in some cases, there is significant anxiety and motor agitation; in severe cases, psychotic symptoms such as hallucinations and delusions may occur. Each episode lasts at least 2 weeks, more than long, or even years, and most cases have a tendency to have recurrent episodes, most of which can be alleviated, and some of which can have residual symptoms or become chronic. The onset of depression (and suicidal events) has begun to trend toward the development of a population of younger age (university, or even middle and primary school students). In conclusion, great importance is needed to science popularization, prevention and treatment of depression.
At present, the western medicines for treating various kinds of depression mainly comprise tricyclic antidepressants (TCA for short, and divided into azines, prolines, dibenzos and the like), monoamine oxidase inhibitors (MAOI for short, such as isopropylhydrazine and the like) and 5-HT reuptake inhibitors (SSRI for short, such as fluoxetine and the like), but the western medicines generally have the defects of drug resistance, large toxic and side effects and the like, so that the search for the antidepressant medicines with safety, high efficiency and small side effects is particularly important, and especially the natural antidepressant medicines becomes a research hotspot in the field.
Chinese patent application CN201810529939.5 discloses a traditional Chinese medicine composition for resisting depression and anxiety, which comprises, by weight, 10-20 parts of ligusticum chuanxiong hort, 5-15 parts of bighead atractylodes rhizome, 4-12 parts of angelica sinensis, 3-9 parts of inula flower, 4-10 parts of mangnolia officinalis, 5-12 parts of medicinal cyathula root, 6-16 parts of raw ochre, 4-10 parts of spina date seed, 5-12 parts of albizia julibrissin, 2-6 parts of longan, 3-9 parts of rose, 5-10 parts of mint, 2-6 parts of Chinese date, 1-3 parts of lily, 2-9 parts of cucumis metuli, 4-10 parts of amomum tsao-ko, 4-10 parts of dutchmanspipe root and 2-4 parts of rehmannia glutinosa. The added ligusticum chuanxiong hort has the effects of clearing away heat and toxic materials; the added rhizoma Atractylodis has effects of nourishing heart and tonifying liver; the added inula flower can enhance the immunity of the human body; the added magnolia officinalis has the effect of reducing blood sugar; the added radix cyathulae has the effects of benefiting heart and spleen and tonifying qi and blood; the added raw ochre has the effects of relieving restlessness and soothing nerves; the added birthwort root has the effects of calming heart and soothing nerves; the traditional Chinese medicine prepared by the mixture has the effects of hypnosis, depression resistance and appetite enhancement, and has no toxic or side effect on human bodies after being taken for a long time.
Chinese patent application CN201610868246.X discloses a Chinese medicinal composition for effectively resisting depression and its preparation method, which is characterized in that the components and their parts by mass of the Chinese medicinal composition are as follows: 30-120 g of radix curcumae, 100-200 g of tuber fleeceflower stem, 60-160 g of spina date seed, 30-120 g of ginseng, 30-120 g of dried orange peel, 30-70 g of American ginseng, 100-320 g of mother-of-pearl, 30-120 g of schisandra chinensis and 60-160 g of radix asparagi.
At present, the medicines for treating depression still mainly comprise western medicines, most of the traditional Chinese medicine compositions are directly prepared from traditional Chinese medicinal materials, and the traditional Chinese medicine compositions are complex in components and can possibly generate other synergistic effects to influence the treatment of depression. In view of the above, the application provides a pharmaceutical composition for relieving depression and a preparation method thereof, which can effectively relieve depression, are simple to prepare and basically have no toxic or side effect.
Disclosure of Invention
The invention aims to provide a medicinal composition for relieving depression and a preparation method thereof, which have the advantages of effective relief of depression, simple preparation and basically no toxic or side effect, and can reduce blood pressure and maintain the normal function of thyroid by adding a component for reducing blood pressure.
In order to achieve the purpose, the technical scheme of the invention is as follows:
in one aspect, the invention provides a pharmaceutical composition for relieving depression, which comprises berberine, liensinine, lycium barbarum polysaccharide, folic acid compounds and fish oil.
Preferably, the pharmaceutical composition comprises, by weight, 10-30 parts of berberine, 2-8 parts of liensinine, 5-15 parts of lycium barbarum polysaccharide, 0.001-0.01 part of folic acid compounds and 5-15 parts of fish oil.
Further preferably, the weight ratio of the berberine to the liensinine to the folic acid compounds is 20: 5: 0.005.
most preferably, the pharmaceutical composition comprises 20 parts of berberine, 5 parts of liensinine, 10 parts of lycium barbarum polysaccharide, 0.005 part of folic acid compound and 10 parts of fish oil in parts by weight.
Preferably, the pharmaceutical composition further comprises the following components: iodine, calcium, selenium, B vitamins and amino acids.
Further preferably, the pharmaceutical composition further comprises the following components in parts by weight: 0.005-0.1 part of iodine, 0.005-0.1 part of calcium, 0.005-0.1 part of selenium, 0.01-0.1 part of B vitamins and 0.001-0.1 part of amino acid.
Most preferably, the pharmaceutical composition further comprises the following components in parts by weight: 0.01 part of iodine, 0.01 part of calcium, 0.01 part of selenium, 0.05 part of B vitamins and 0.01 part of amino acid.
Preferably, the folic acid compounds are at least one of folic acid, leucovorin, L-methyl folic acid, pharmaceutically acceptable salts of folic acid, active metabolites of folic acid or pharmaceutically acceptable salts of folic acid and substances capable of metabolizing and/or generating folic acid in vivo, and more preferably L-methyl folic acid.
Preferably, the B vitamins are mixed B vitamins of B1, B2, B6 and B12, and more preferably B1, B2, B6 and B12 in a ratio of 1: 1: 4: 1 weight ratio of mixed B vitamins.
In another aspect, the present invention further provides a preparation method of the above pharmaceutical composition, comprising the following steps: weighing the components according to the prescription amount, respectively, smashing into powder with the granularity range of 30-40 meshes, filtering into fine powder with gauze with the granularity range of 80-120 meshes, and uniformly mixing.
Finally, the invention also provides a pharmaceutical preparation or a health-care product preparation of the pharmaceutical composition, which is any one of tablets, capsules, oral liquid, syrup, granules, pills, powder, ointment, pellets, injections, suppositories, creams, sprays, dripping pills, patches, sustained-release preparations and controlled-release preparations.
The invention has the beneficial effects that:
(1) the traditional Chinese medicine composition can effectively relieve depression;
(2) hypertension, thyroid gland and the like are closely inseparable from depression, and part of components in the composition have the functions of relieving depression and maintaining the thyroid gland, so that the blood pressure is reduced while the depression is relieved, the normal function of the thyroid gland is maintained, and the treatment is facilitated;
(3) the traditional Chinese medicine composition provided by the invention basically has no toxic or side effect and is safe to use.
Detailed Description
The present invention will be further explained with reference to specific examples in order to make the technical means, the technical features, the technical objectives and the effects of the present invention easier to understand, but the following examples are only preferred embodiments of the present invention, and not all embodiments of the present invention. Based on the embodiments in the implementation, other embodiments obtained by those skilled in the art without any creative efforts belong to the protection scope of the present invention. In the following examples, unless otherwise specified, all the operations were performed by conventional methods, all the equipments were performed by conventional methods, and the materials of the equipments used in the respective examples were the same.
Preparation of the experiment:
table 1.
Examples 1 to 4
The formulations of examples 1-4 are shown in the following table:
table 2.
| Parts by weight | Example 1 | Example 2 | Example 3 | Example 4 |
| Berberine | 20 | 20 | 10 | 30 |
| Lotus seed plumule alkali | 5 | 5 | 2 | 8 |
| Lycium barbarum polysaccharides | 10 | 8 | 15 | 5 |
| L-methyl Folic acid | 0.005 | 0.005 | 0.01 | 0.001 |
| Fish oil | 10 | 12 | 15 | 5 |
Example 5
The same as in example 1, except that folic acid was used in place of L-methylfolic acid.
Examples 6 to 8
The formulations of examples 6-8 are shown in the following table:
table 3.
| Parts by weight | Example 6 | Example 7 | Example 8 |
| Berberine | 20 | 20 | 20 |
| Lotus seed plumule alkali | 5 | 5 | 5 |
| Lycium barbarum polysaccharides | 10 | 10 | 10 |
| L-methyl Folic acid | 0.005 | 0.005 | 0.005 |
| Fish oil | 10 | 10 | 10 |
| Iodine | 0.01 | 0.005 | 0.1 |
| Calcium carbonate | 0.01 | 0.005 | 0.1 |
| Selenium | 0.01 | 0.005 | 0.1 |
| B vitamins | 0.05 | 0.01 | 0.1 |
| Amino acids | 0.01 | 0.005 | 0.1 |
Comparative examples 1 to 3
The formulations of comparative examples 1-3 are shown in the following table:
table 4.
| Parts by weight | Comparative example 1 | Comparative example 2 | Comparative example 3 |
| Berberine | 20 | 20 | 20 |
| Lotus seed plumule alkali | - | 5 | 5 |
| Lycium barbarum polysaccharides | 10 | 10 | - |
| L-methyl Folic acid | 0.005 | - | 0.005 |
| Fish oil | 10 | 10 | 10 |
The pharmaceutical compositions in the above examples were prepared according to the following steps: weighing the components according to the dosage of the formula, respectively, mashing into powder, screening out the powder with the granularity range of 30-40 meshes, filtering the powder into fine powder with gauze, screening out the powder with the granularity range of 80-120 meshes, and uniformly mixing to obtain the product.
Detection of drug efficacy
1. Experiment of immobility of tail suspension
1.1 grouping and dose: 130 male Kunming mice (20 + -2 g) were randomly divided into 13 groups (blank, positive, examples 1-8, comparative examples 1-3, respectively) of 10 mice each. Wherein, the Chinese medicinal compositions prepared in the groups of examples 1-8 and the groups of comparative examples 1-3 are respectively administered to the groups of examples 1-8 and the groups of comparative examples 1-3 at an administration dose of 1 g/kg; fluoxetine was administered to the positive group at a dose of 15 mg/kg.
1.2 administration mode: the medicines are all prepared into suspension with ultrapure water, and the suspension is administrated by intragastric administration according to 0.1mL/10g, and the blank group is administrated with physiological saline with the same dosage for 7 days continuously.
1.3 Experimental methods: the time is two points from 9 am to afternoon, 1h after the last administration, the tail tip lcm of each group of mice is fixed on the hook by an adhesive tape to be in an overhung state, the head part of each group of mice is about 10cm away from the experiment table, the sight of the mice is isolated by a baffle plate, the mice start to struggle violently to get rid of, the back movement gradually weakens, an intermittent immobile state occurs, the immobile state time is longer and longer, the immobile state time of more than 3s is effective time, and the accumulated effective time of the mice in 6min of overhung is recorded.
2. Experiment of forced swimming immobility
1.1 grouping and dose: 130 male Kunming mice (20 + -2 g) were randomly divided into 13 groups (blank, positive, examples 1-8, comparative examples 1-3, respectively) of 10 mice each. Wherein, the Chinese medicinal compositions prepared in the groups of examples 1-8 and the groups of comparative examples 1-3 are respectively administered to the groups of examples 1-8 and the groups of comparative examples 1-3 at an administration dose of 1 g/kg; fluoxetine was administered to the positive group at a dose of 15 mg/kg.
1.2 administration mode: the medicines are all prepared into suspension with ultrapure water, and the suspension is administrated by intragastric administration according to 0.1mL/10g, and the blank group is administrated with physiological saline with the same dosage for 7 days continuously.
1.3 Experimental methods: the time is from 9 am to 2 pm, 1h after the last administration, the mice are individually placed into a container filled with water, the water temperature is 24 ℃, and the water depth is required: the mouse is just enough to touch the bottom of the container but not to support the body. The mouse starts to force swimming and struggles to climb upwards or submerge into the bottom of the container, the later movement is gradually weakened, an intermittent immobile state occurs, the time of the immobile state is longer and longer, the time of the immobile state of more than 3s is the effective time, and the accumulated effective time of the mouse in water within 6min is recorded.
3. Discussion of results
The immobility time statistics are shown in the following table:
table 5.
| Group of | Suspension tail motionless time(s) | Forced swimmingImmobility time of swimming(s) |
| Blank group | 119.2±27.7 | 125.8±30.6 |
| Positive group | 67.3±16.4** | 58.7±18.4** |
| Example 1 | 66.5±13.8** | 58.0±38.3** |
| Example 2 | 68.7±36.7* | 59.5±25.5** |
| Example 3 | 72.3±32.8* | 62.7±39.4* |
| Example 4 | 70.8±28.4* | 63.1±31.8* |
| Example 5 | 70.2±25.1* | 61.2±20.8** |
| Example 6 | 63.1±19.6** | 53.1±26.4** |
| Example 7 | 63.9±26.3** | 55.6±29.1** |
| Example 8 | 65.4±34.7** | 56.8±28.3** |
| Comparative example 1 | 84.3±36.0 | 81.9±30.2* |
| Comparative example 2 | 81.5±26.4* | 78.6±19.7* |
| Comparative example 3 | 78.9±27.2* | 73.2±37.9* |
Note: p <0.05, P <0.01, compared to blank group
It can be seen that the traditional Chinese medicine composition prepared in the embodiments 1 to 8 of the invention can play a good role in relieving depression, and can basically achieve the same relieving effect as the existing antidepressant drug fluoxetine hydrochloride. From the experimental results, the effect of relieving depression was further improved by adding auxiliary ingredients such as iodine and calcium, and the effect of relieving depression was better in example 1 without adding auxiliary ingredients such as iodine and calcium.
4. Dose test
20 male Kunming mice (20 +/-2 g) were randomly divided into 2 groups of 10, and the Chinese medicinal composition of example 1 was administered at 2g/kg in the medium dose group and 3g/kg in the high dose group, and the group of example 1 in Table 5 was administered at 1g/kg in the low dose group, and the tail suspension and forced swimming tests were performed according to the above-mentioned method, and the results are as follows:
table 6.
| Group of | Suspension tail motionless time(s) | Forced swimming immobility time(s) |
| Blank group | 119.2±27.7 | 125.8±30.6 |
| Positive group | 67.3±16.4** | 58.7±18.4** |
| Low dose group | 66.5±13.8** | 58.0±38.3** |
| Middle dose group | 61.4±22.8** | 48.7±26.7** |
| High dose group | 53.4±18.3** | 42.9±21.2** |
Note: p <0.05, P <0.01, compared to blank group
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. A pharmaceutical composition for relieving depression is characterized by comprising berberine, liensinine, lycium barbarum polysaccharide, folic acid compounds and fish oil.
2. The pharmaceutical composition according to claim 1, which comprises 10-30 parts of berberine, 2-8 parts of liensinine, 5-15 parts of lycium barbarum polysaccharide, 0.001-0.01 part of folic acid compounds and 5-15 parts of fish oil by weight, preferably, the weight ratio of the berberine to the liensinine to the folic acid compounds is 20: 5: 0.005.
3. the pharmaceutical composition according to claim 2, comprising 20 parts of berberine, 5 parts of liensinine, 10 parts of lycium barbarum polysaccharide, 0.005 parts of folic acid compounds and 10 parts of fish oil in parts by weight.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition further comprises the ingredients: iodine, calcium, selenium, B vitamins and amino acids.
5. The pharmaceutical composition according to claim 4, further comprising the following components in parts by weight: 0.005-0.1 part of iodine, 0.005-0.1 part of calcium, 0.005-0.1 part of selenium, 0.01-0.1 part of B vitamins and 0.001-0.1 part of amino acid.
6. The pharmaceutical composition according to claim 5, further comprising the following components in parts by weight: 0.01 part of iodine, 0.01 part of calcium, 0.01 part of selenium, 0.05 part of B vitamins and 0.01 part of amino acid.
7. The pharmaceutical composition according to any one of claims 1 to 3, wherein the folic acid compounds are at least one of folic acid, leucovorin, L-methylfolic acid, pharmaceutically acceptable salts of folic acid, active metabolites of folic acid or pharmaceutically acceptable salts of folic acid, and substances metabolizable and/or generating folic acid in vivo, preferably L-methylfolic acid.
8. The pharmaceutical composition according to any one of claims 1 to 3, wherein the B vitamins are mixed B vitamins of B1, B2, B6 and B12, preferably B1, B2, B6 and B12 according to 1: 1: 4: 1 weight ratio of mixed B vitamins.
9. A process for the preparation of a pharmaceutical composition according to any one of claims 1 to 8, comprising the steps of: weighing the components according to the prescription amount, respectively, smashing into powder with the granularity range of 30-40 meshes, filtering into fine powder with gauze with the granularity range of 80-120 meshes, and uniformly mixing.
10. The pharmaceutical preparation or nutraceutical preparation of the pharmaceutical composition of any one of claims 1 to 8, characterized in that it is selected from any one of tablets, capsules, oral liquids, syrups, granules, pills, powders, ointments, pellets, injections, suppositories, creams, sprays, drop pills, patches, sustained release formulations, controlled release formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111443408.2A CN114224919B (en) | 2021-11-30 | 2021-11-30 | Pharmaceutical composition for relieving depression and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111443408.2A CN114224919B (en) | 2021-11-30 | 2021-11-30 | Pharmaceutical composition for relieving depression and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114224919A true CN114224919A (en) | 2022-03-25 |
| CN114224919B CN114224919B (en) | 2024-06-25 |
Family
ID=80752137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111443408.2A Active CN114224919B (en) | 2021-11-30 | 2021-11-30 | Pharmaceutical composition for relieving depression and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114224919B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622958A (en) * | 2012-08-25 | 2014-03-12 | 北京以岭药业有限公司 | Application of tetrahydroproberberine compounds to prepare antidepressants |
| US20150164870A1 (en) * | 2012-11-19 | 2015-06-18 | Dalian Institute Of Chemical Pysics, Chinese Academy Of Sciences | Use and preparation method of berberine compounds |
| CN108420826A (en) * | 2018-06-14 | 2018-08-21 | 吉林大学 | Polysaccharides is in the purposes prepared in treating or alleviating the drug of depression and includes its pharmaceutical composition |
| WO2020262970A1 (en) * | 2019-06-25 | 2020-12-30 | 동아대학교 산학협력단 | Composition for preventing or treating diseases caused by mitochondrial dysfunction |
| CN112546120A (en) * | 2020-11-24 | 2021-03-26 | 北京斯利安药业有限公司 | Product containing folic acid for relieving anxiety |
| CN112641100A (en) * | 2020-11-24 | 2021-04-13 | 北京斯利安药业有限公司 | Anti-depression electuary containing folic acid |
-
2021
- 2021-11-30 CN CN202111443408.2A patent/CN114224919B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622958A (en) * | 2012-08-25 | 2014-03-12 | 北京以岭药业有限公司 | Application of tetrahydroproberberine compounds to prepare antidepressants |
| US20150164870A1 (en) * | 2012-11-19 | 2015-06-18 | Dalian Institute Of Chemical Pysics, Chinese Academy Of Sciences | Use and preparation method of berberine compounds |
| CN108420826A (en) * | 2018-06-14 | 2018-08-21 | 吉林大学 | Polysaccharides is in the purposes prepared in treating or alleviating the drug of depression and includes its pharmaceutical composition |
| WO2020262970A1 (en) * | 2019-06-25 | 2020-12-30 | 동아대학교 산학협력단 | Composition for preventing or treating diseases caused by mitochondrial dysfunction |
| CN112546120A (en) * | 2020-11-24 | 2021-03-26 | 北京斯利安药业有限公司 | Product containing folic acid for relieving anxiety |
| CN112641100A (en) * | 2020-11-24 | 2021-04-13 | 北京斯利安药业有限公司 | Anti-depression electuary containing folic acid |
Non-Patent Citations (2)
| Title |
|---|
| 吕利, 刘庆春, 杜金赞: "叶酸与抑郁症的关系", 武警医学, no. 01, 1 January 1999 (1999-01-01) * |
| 牛玉虎;郭国英;弓韬;张栋;王惠珍;: "黄连素对Aβ诱导的大鼠抑郁行为的缓解作用及其相关机制", 山西医科大学学报, vol. 48, no. 06, pages 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114224919B (en) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108671140B (en) | Composition for improving sleep and application thereof | |
| CN102764339B (en) | Maca composition for improving sexual dysfunction and preparation method and application thereof | |
| CN107495367B (en) | Food, health-care product or pharmaceutical composition for improving anoxia resistance and preparation method and application thereof | |
| CN103055057A (en) | Plant weight-losing and fat-reducing composite compatible to L-carnitine | |
| CN110237204B (en) | A composition with brain strengthening/cranial nerve regulating effects | |
| CN101015605A (en) | Health-care food for improving sleeping and its preparing process | |
| KR20100106324A (en) | Antimelancholic medicine prepared with jujube camp material | |
| JP4803969B2 (en) | Method for producing granules containing plant extract | |
| EP3307294B1 (en) | Pharmaceutical composition for treatment of depression and preparation method thereof | |
| CN114224919A (en) | Pharmaceutical composition for relieving depression and preparation method thereof | |
| CN101199669A (en) | Chinese medicine compound agent for treating female sperm quality lowclass | |
| CN103876137A (en) | Health-care traditional Chinese medicine product with function of improving sleep | |
| CN1872327B (en) | Composition of medicine for treating diarrhea | |
| CN101049435A (en) | Method of preparing nutriment for preventing brain dementia of middle-aged persons and elderly persons | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| CN110960605A (en) | Eye-protecting traditional Chinese medicine composition | |
| CN104906339B (en) | It is a kind of that there is the health food granule for improving sleep function | |
| CN113057994B (en) | Patrinia scabiosaefolia active component, preparation method and application thereof | |
| CN1265831C (en) | Compound ginseng saponin biological preparation for inhibiting tumour and its preparation method | |
| CN107693618B (en) | Pharmaceutical composition for treating kidney deficiency and preparation method and application thereof | |
| CN104382972A (en) | Composition of paecilomyces hepialid, ginseng and pseudo-ginseng and preparation method of composition | |
| CN1170578C (en) | Composite medicine for improving memory and intelligence | |
| CN113599433A (en) | Traditional Chinese medicine composition for treating insomnia and preparation method and application thereof | |
| CN104645245B (en) | A kind of preparation method for Menopause depression pharmaceutical preparation | |
| CN104922201A (en) | Healthcare food tablet with function of improving sleep |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |